Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05789303 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 1 to 2
    • Eligibility criteria expanded, about 40 words
    • Secondary endpoints: details revised at 2 of 5 entries
  2. 2 versions Re-verified since Nov 20, 2024, no change to tracked fieldsv4-v5
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 1, 2023 to May 30, 2023
    • Site details revised
    v3
  4. Enrollment target: 55 to 83v2 Show 4 more changesShow less
    • Primary endpoints: 1 to 2
    • Secondary endpoints revised (5)
    • Collaborators: 1 to 2
    • Study arms: 1 to 2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Doctors leading this study hope to learn if the combination of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone is effective and safe when given to people who have multiple myeloma that has gotten worse and is not responding to standard drugs that are used for treating multiple myeloma, including chimeric antigen receptor T-cell therapy. Participation in this research will last about 6 -24 months, but it may be less or more depending on your response to treatment.
Trial Details
NCT Number NCT05789303
Lead Sponsor University of Chicago
Collaborators: GlaxoSmithKline, Amgen
Conditions
(from sponsor)		 Multiple Myeloma, Relapse Multiple Myeloma
Related terms Multiple Myeloma
Enrollment 83 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov